

# GraÅ¼yna ChÅoÅ,-Rzepa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4224758/publications.pdf>

Version: 2024-02-01

40  
papers

416  
citations

840776

11  
h-index

839539

18  
g-index

41  
all docs

41  
docs citations

41  
times ranked

458  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 381-394.	5.5	37
2	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 212-221.	3.0	31
3	A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF- $\beta$ 2 Signaling and Activation of cAMP/PKA Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4008.	4.1	28
4	Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 517-533.	5.5	27
5	Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research. <i>Current Drug Targets</i> , 2018, 20, 122-143.	2.1	23
6	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT1A, 5-HT2A, and 5-HT7 serotonin receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5239-5250.	3.0	21
7	Novel anilide and benzamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112437.	5.5	19
8	New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112854.	5.5	16
9	New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation. <i>Pharmacological Reports</i> , 2013, 65, 15-29.	3.3	15
10	Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling. <i>European Journal of Pharmacology</i> , 2019, 865, 172779.	3.5	13
11	7-3-Chlorophenylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione as a serotonin receptor ligands with potential antidepressant activity. <i>Pharmacological Reports</i> , 2014, 66, 505-510.	3.3	12
12	Comparative Assessment of the New PDE7 Inhibitor $\alpha$ -GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach. <i>Pharmaceutical Research</i> , 2020, 37, 19.	3.5	12
13	Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. <i>Bioorganic Chemistry</i> , 2021, 117, 105409.	4.1	11
14	Analgesic and anti-inflammatory activity of 7-substituted purine-2,6-diones. <i>Pharmacological Reports</i> , 2014, 66, 996-1002.	3.3	10
15	New 7-arylpiperazinylalkyl-8-morpholin-4-yl-purine-2,6-dione derivatives with anxiolytic activity $\alpha$ Synthesis, crystal structure and structure-activity study. <i>Journal of Molecular Structure</i> , 2014, 1067, 243-251.	3.6	10
16	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 1048-1062.	5.2	10
17	In Vitro Biotransformation, Safety, and Chemopreventive Action of Novel 8-Methoxy-Purine-2,6-Dione Derivatives. <i>Applied Biochemistry and Biotechnology</i> , 2018, 184, 124-139.	2.9	10
18	Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2020, 27, 5351-5373.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. <i>Current Drug Targets</i> , 2019, 20, 1652-1669.	2.1	10
20	Aminoalkyl Derivatives of 8-Alkoxy-purine-2,6-diones: Multifunctional 5-HT <sub>1A</sub> /5-HT <sub>7</sub> Receptor Ligands and PDE Inhibitors with Antidepressant Activity. <i>Archiv Der Pharmazie</i> , 2016, 349, 889-903.	4.1	9
21	Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2021, 28, 1731-1745.	2.4	9
22	Analgesic activity of new 8-methoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl derivatives with carboxylic, ester or amide moieties. <i>Pharmacological Reports</i> , 2015, 67, 9-16.	3.3	8
23	Synthesis of 8-alkoxy-1,3-dimethyl-2,6-dioxopurin-7-yl-substituted acetohydrazides and butanehydrazides as analgesic and anti-inflammatory agents. <i>Heterocyclic Communications</i> , 2015, 21, 273-278.	1.2	7
24	Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 49, 128318.	2.2	7
25	Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. <i>Current Medicinal Chemistry</i> , 2019, 26, 4885-4913.	2.4	7
26	New Arylpiperazinylalkyl Derivatives of 8-Alkoxy-purine-2,6-dione and Dihydro[1,3]oxazolo[2,3-f]purinedione Targeting the Serotonin 5-HT <sub>1A</sub> /5-HT <sub>2A</sub> /5-HT <sub>7</sub> and Dopamine D <sub>2</sub> Receptors. <i>Archiv Der Pharmazie</i> , 2015, 348, 242-253.	4.1	6
27	N-(4-Arylpiperazinoalkyl)acetamide derivatives of 1,3- and 3,7-dimethyl-1H-purine-2,6(3H,7H)-diones and their 5-HT <sub>6</sub> , 5-HT <sub>7</sub> , and D <sub>2</sub> receptors affinity. <i>Heterocyclic Communications</i> , 2015, 21, 13-18.	1.2	6
28	Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents. <i>Current Medicinal Chemistry</i> , 2020, 27, 6658-6681.	2.4	6
29	PK/PD Modeling of the PDE7 Inhibitor GRMS-55 in a Mouse Model of Autoimmune Hepatitis. <i>Pharmaceutics</i> , 2021, 13, 597.	4.5	4
30	Pan-Phosphodiesterase Inhibitors Attenuate TGF- $\beta$ -Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. <i>Pharmaceutics</i> , 2022, 15, 423.	3.8	4
31	Structure-cardiovascular activity relationships in a group of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3-aminopropyl)-3,7-dihydro-1H-purine-2,6-diones. <i>Pharmacological Reports</i> , 2011, 63, 476-486.	3.3	3
32	Determination of ligand efficiency indices in a group of 7H-purine-2,6-dione derivatives with psychotropic activity using micellar electrokinetic chromatography. <i>Electrophoresis</i> , 2018, 39, 2446-2453.	2.4	3
33	Structure-5-HT <sub>2</sub> Receptor Affinity Relationship in a New Group of Arylpiperazinylalkyl Derivatives of 8-Dialkylamino-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione. <i>Archiv Der Pharmazie</i> , 2016, 349, 774-784.	1	2
34	Diabetic Theory in Anti-Alzheimer's Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors. <i>Current Medicinal Chemistry</i> , 2021, 28, 3535-3553.	2.4	2
35	A new class of 5-HT <sub>1A</sub> receptor antagonists with procognitive and antidepressant properties. <i>Future Medicinal Chemistry</i> , 2021, 13, 1497-1514.	2.3	2
36	Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2021, 28, 6082-6094.	2.4	2

#	ARTICLE	IF	CITATIONS
37	ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF NEW ANALOGUES OF HC-030031: A TRPA1 CHANNEL ANTAGONIST. <i>Acta Poloniae Pharmaceutica</i> , 2020, 77, 113-119.	0.1	1
38	Synthesis and cardiovascular activity of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3- <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50,702 Td (pi</i>	0.3	1
39	Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases. <i>Pharmaceutics</i> , 2022, 14, 1090.	4.5	1
40	Design and synthesis of new anilide and benzylamide derivatives as potential multifunctional ligands with procognitive and antidepressant activity. <i>Postępy Polskiej Medycyny i Farmacji</i> , 2022, 9, 1-8.	0.0	0